Falkmer, Ursula Gerda Inge

Fristrup, C.

Hansen, C.P.

Ladekarl, M.

Mortensen, F.V.

Mortensen, M.B.

Pfeiffer, P

Poulsen, Laurids Østergaard

Rasmussen, Louise Skau

Sall, Mogens

Skuladottir, H

Vittrup, B

Yilmaz, Mette Karen

Østerlind, K.

English

    Aalborg UniversitetInitial treatment and survival in a national unselected Danish cohort of 4163 patientswith pancreatic cancerRasmussen, Louise Skau; Vittrup, B; Ladekarl, M.; Pfeiffer, P; Yilmaz, Mette Karen; Poulsen,Laurids Østergaard; Østerlind, K.; Skuladottir, H; Hansen, C.P.; Mortensen, M.B.; Mortensen,F.V.; Sall, Mogens; Falkmer, Ursula Gerda Inge; Fristrup, C.Publication date:2019Document VersionPublisher's PDF, also known as Version of recordLink to publication from Aalborg UniversityCitation for published version (APA):Rasmussen, L. S., Vittrup, B., Ladekarl, M., Pfeiffer, P., Yilmaz, M. K., Poulsen, L. Ø., Østerlind, K., Skuladottir,H., Hansen, C. P., Mortensen, M. B., Mortensen, F. V., Sall, M., Falkmer, U. G. I., & Fristrup, C. (2019). Initialtreatment and survival in a national unselected Danish cohort of 4163 patients with pancreatic cancer. Posterpresented at First Scandinavian Baltic Pancreas Symposium 2019, Kolding, Denmark.General rightsCopyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright ownersand it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.            ? Users may download and print one copy of any publication from the public portal for the purpose of private study or research.            ? You may not further distribute the material or use it for any profit-making activity or commercial gain            ? You may freely distribute the URL identifying the publication in the public portal ?Take down policyIf you believe that this document breaches copyright please contact us at vbn@aub.aau.dk providing details, and we will remove access tothe work immediately and investigate your claim.Downloaded from vbn.aau.dk on: November 25, 2020Abbreviations: Gem: gemcitabine, FOLFIRINOX: 5-flourouracil, leucovorin, irinotecan and oxaliplatin, Cap: capecitabine, S1: tegafur/gimeracil/oteracil, Pac: nab-paclitaxel.*31 patients with other regimens as initial treatment than those listed were excluded.Regimen* Patients  No.Median overall survival, months  (95% confidence interval)Gem monotherapy 938   5.1  (4.8- 5.6)FOLFIRINOX 435 10.0  (9.2-11.0)GemCap 134   8.4   (6.9-9.1)GemS1 114   8.9   (7.2-10.3)GemPac 94   6.7   (5.5-8.7)Figure 3• sfkInitial treatment and survival in a national unselected Danish cohort of 4163 patients with pancreatic cancerL.S. Rasmussen1, B. Vittrup2, M. Ladekarl3, P. Pfeiffer4, M.K. Yilmaz1, L.Ø. Poulsen1, K. Østerlind5, H. Skuladottir6, C.P. Hansen7, M.B. Mortensen8, F.V Mortensen9, M. Sall10, U.G. Falkmer1, C. Fristrup11 1Department of Oncology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark; Department of Clinical Medicine, Faculty of Medicine, Aalborg University, Denmark, 2Department of Oncology, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark, 3Department of Oncology, Aarhus University Hospital, Aarhus, Denmark,4Department of Oncology, Odense University Hospital, Odense, Denmark, 5Department of Oncology, North Sealand Hospital, Hillerød, Denmark, 6Department of Oncology, Herning Hospital, Herning, Denmark, 7Department of Surgical Gastroenterology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark,8Odense Pancreas Center (OPAC), Department of Surgery, Odense University Hospital, Odense, Denmark, 9Department of Surgical Gastroenterology, Aarhus University Hospital, Aarhus, Denmark, 10Department of Surgical Gastroenterology, Aalborg University Hospital, Aalborg, Denmark, 11Danish Pancreatic Cancer Database; Department of Surgery, Odense University Hospital, Odense, Denmark ResultsBackgroundNationwide data on the efficacy of primary treatment on overall survival (OS) in an entirely unselected population of patients with pancreatic cancer (PC) have not been reported before. Material and Methods• From 1 May 2011 to 30 April 2016, 4260 patients were identified in the national Danish Pancreatic Cancer Database (DPCD), Figure 1.• Patients’ characteristics are presented in Table 1.• OS was analysed from the date of the initial treatment, either resection or chemotherapy or from the date of diagnosis in case of best supportive care (BSC). Last clinical follow-up was 10 September 2017.• Treatment and clinical outcome are presented in Figure 2, Table 2 and Figure 3.• Resected lymph node negative patients had the longest survival.• Patients initially treated with chemotherapy (mono or combination) had slightly shorter median OS than found in randomised  controlled trials. • The outcome of gemcitabine monotherapy was poor, possibly  reflecting less treatment effect and selection of less fit patients. • To reduce the group of BSC patients, new diagnostic methods are required.ConclusionResectionLymph node metastases* Patients  No.Median overall survival, months  (95% confidence interval)N- 215 36.9 (28.6-44.7)N+ 465 17.5 (15.4-20.1)Abbreviations; N-: Without lymph node metastases, N+: With lymph node metastases.*38 patients without histopathological reports on lymph node status were excluded. Table 2Poster no. 743Louise Skau RasmussenMD, PhD student, loskr@rn.dkDepartment of Oncology, Aalborg University Hospital, Denmark Figure 1*Excluded: Preoperative/neoadjuvant chemotherapy followed by resection: 56, other malignancies: 26, incorrect registration of treatment: 13, lost to follow-up: 2. Excluded*N=97PCN=4260IncludedN=4163ResectionN=718(17%)ChemotherapyN=1746(43%)Best supportive careN=1699(40%)AimTo investigate the effect of initial treatment on OS in all patients with PC in Denmark diagnosed in a recent five-year period.ChemotherapyResection  (n=718)Chemotherapy  (n=1746)BSC  (n=1699)All  (n=4163)Age;years (median and range) 67 (13-86) 68 (34-90) 74 (24-100) 70 (13-100)GenderFemale 338 (47%) 813 (47%) 843 (50%) 1994 (48%)Male 380 (53%) 933 (53%) 856 (50%) 2164 (52%)Charlson comorbidity index0-2 561 (78%) 1301 (75%) 1024 (60%) 2886 (69%)>3 157 (22%) 445 (25%) 675 (40%) 1277 (31%)M-status*0 718 (100%) 905 (52%) 847 (50%) 1752 (51%)1 0 (0%) 841 (48%) 852 (50%) 1693 (49%)DiagnosisPathology 718 (100%) 1642 (94%) 1288 (76%) 3648 (88%)Clinical 0 (0%) 104 (6%) 411 (24%) 515 (12%)Abbreviation; BSC: Best suppotive care. * M-status; M1: patients coded with metastatic disease in DPCD within 60 days from diagnosis.Table 1Treatment PatientsNo.Median overall survival, months  (95% confidence interval)Resection 718 21.9 (20.0-24.2)Chemotherapy 1746 6.9 (6.4-7.3)BSC* 1697 1.6 (1.5-1.7)Abbreviation; BSC: Best supportive care. *Two patients were excluded from the survival analyses due to diagnosis date = date of death.All patientsFigure 2

Initial treatment and survival in a national unselected Danish cohort of 4163 patients with pancreatic cancer

https://vbn.aau.dk/ws/files/317612798/Rasmussen_Poster_esmo_2018.pdf

Initial treatment and survival in a national unselected Danish cohort of 4163 patients with pancreatic cancer

Abstract

Similar works

Full text

Available Versions

VBN